Zevra Therapeutics, Inc
Zevra Therapeutics is a U.S.-based rare-disease pharmaceutical company focused on developing, commercializing, and expanding therapies for small patient populations with high unmet need. Its portfolio includes approved medicines, late-stage product candidates, and partnered assets spanning rare metabolic, neurologic, and genetic disorders.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved medicines sold for rare disease indications, including MIPLYFFA and OLPRUVA.
Royalties and milestone payments from partnered products such as AZSTARYS.
Revenue tied to global expanded access and related reimbursement arrangements.
Late-stage development programs including celiprolol and KP1077 candidates.
Asiakkaat
Zevra sells primarily to specialty pharmacies, distributors, and healthcare systems that dispense rare-disease medicines to patients under physician supervision. Its end users are patients with rare metabolic, neurologic, or genetic disorders, while physicians and treatment centers drive prescribing decisions and access pathways. The company also receives revenue from partners through royalties and milestones tied to licensed products.
Dispense approved rare-disease medicines such as MIPLYFFA to patients in the United States.
Buy and distribute MIPLYFFA in the EU and select non-European territories.
Prescribe and manage therapy for rare-disease patients, driving product adoption.
Generate royalty and milestone income from partnered assets such as AZSTARYS.
Use the therapies for chronic rare-disease treatment and access programs.
Strategia
Zevra is focused on building a rare-disease franchise around commercial execution, late-stage development, and targeted business development. The company is prioritizing MIPLYFFA commercialization and geographic expansion, maintaining OLPRUVA, advancing celiprolol, and adding assets that fit its rare-disease infrastructure.
A marketed rare-disease product anchors the franchise and builds commercial infrastructure.
Late-stage programs can extend the company beyond a single commercial product.
Acquisitions and partnerships can broaden the portfolio without building everything internally.
Concentrating on late-stage and outsourced development improves capital efficiency.
Maantiede
The company is headquartered in the United States and commercializes MIPLYFFA there, while also pursuing broader access in Europe and select territories outside Europe through distributors and expanded access channels. OLPRUVA has rights in Geographical Europe through a licensing arrangement, and the company is pursuing European regulatory approval for MIPLYFFA. Geography matters because rare-disease commercialization depends on local regulatory approvals, reimbursement systems, and distribution partners.
Riskit
Zevra depends on regulatory approvals, market acceptance, and third-party distribution to commercialize its rare-disease products. Its pipeline and international expansion also expose it to clinical, reimbursement, supply-chain, and foreign-operating risks that are common in specialty pharmaceuticals but amplified by small patient populations.
- Dependence on third-party distributors and specialty pharmacy channelsVaikutus: KorkeaTodennäköisyys: Kohtalainen
MIPLYFFA is distributed through a single specialty pharmacy in the U.S. and single distributors in other markets.
Kohdistuu: Product availability and revenue concentration
- Regulatory approval and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercial growth depends on maintaining approvals and obtaining new ones in Europe and for pipeline assets.
Kohdistuu - Market acceptance risk in rare diseasesVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even approved therapies may not gain expected uptake if physicians, payors, or patients prefer alternatives.
Kohdistuu: NPC and other rare-disease indications
- Clinical development riskVaikutus: KorkeaTodennäköisyys: Matala
Late-stage candidates can fail to meet endpoints, delay launches, or require additional studies.
Kohdistuu - Foreign operating and reimbursement riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
International commercialization faces price controls, reimbursement differences, and currency volatility.
Kohdistuu: Europe and select non-U.S. territories
Kirjanpito
Harkinnanvaraiset erätRevenue comes from product sales, royalties, milestones, and access reimbursements with different timing rules.
Vaikutus: Can cause quarter-to-quarter volatility in reported revenue
Acquisitions created goodwill that must be tested for recoverability.
Vaikutus: Non-cash impairment could materially affect earnings
Acquired product rights are amortized and reviewed for recoverability.
Vaikutus: Affects operating expense and potential impairment charges
Partnered assets such as AZSTARYS generate variable consideration and contingent receipts.
Vaikutus: Can create uneven revenue recognition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Azitra, Inc.
AZTR · Pharmaceutical Preparations
PTC Therapeutics, Inc
PTCT · Pharmaceutical Preparations
PTC Therapeutics is a U.S.-based global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders.
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Savara Inc
SVRA · Pharmaceutical Preparations
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
Päivitetty: 24.9.2026